Dopamine receptor agonists for Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease (PD) treatment with l-3,4-dihydroxyphenylalanine (l-DOPA) is limited by motor complications.
• Dopamine (DA) agonists offer an alternative by directly stimulating DAergic receptors.

Purpose of the Study:

• To review pre-clinical and clinical data on DA agonists for PD treatment.
• To evaluate the motor, non-motor, and potential neuroprotective effects of second-generation DA agonists.
• To assess the anti-parkinsonian potential of recently developed DA agonists in clinical trials.

Main Methods:

• Review of pre-clinical and clinical studies on DA agonists.
• Focus on second-generation, non-ergolinic DA agonists.
• Inclusion of data from Phase II and III clinical trials for newer DA agonists.

Main Results:

• DA agonists demonstrate significant symptomatic efficacy in PD, though less potent than l-DOPA.
• Extended-release formulations of second-generation DA agonists improve patient compliance.
• Pre-clinical studies suggest neuroprotective properties, but clinical evidence remains inconclusive.

Conclusions:

• DA agonists are valuable throughout PD progression, as monotherapy or adjunct to l-DOPA.
• Current DA agonists offer symptomatic benefits but require further development for enhanced efficacy and reduced side effects.
• Novel DA agonists with improved efficacy and safety profiles are essential for future PD management.